Sachin Jain
Stock Analyst at Bank of America Securities
(3.69)
# 2,159
Out of 5,133 analysts
243
Total ratings
57.8%
Success rate
4.5%
Average return
Main Sectors:
Stocks Rated by Sachin Jain
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: AZN AstraZeneca PLC | Reiterated: Buy | n/a | $13,982.00 | - | 90 | Oct 30, 2026 | |
| LON: GSK GSK plc | Reiterated: Hold | 2,350p | 1,912p | +22.94% | 17 | Oct 28, 2026 | |
| SWX: NOVN Novartis AG | Reiterated: Buy | CHF 150.00 | CHF 134.06 | +11.89% | 34 | Oct 27, 2026 | |
| NVS Novartis AG | Reiterated: Buy | n/a | $160.50 | - | 9 | Oct 27, 2026 | |
| EPA: SAN Sanofi | Reiterated: Hold | €92.00 | €87.60 | +5.02% | 25 | Oct 8, 2026 | |
| ETR: BAYN Bayer Aktiengesellschaft | Reiterated: Buy | €30.00 → €35.00 | €56.52 | -38.08% | 9 | Dec 2, 2025 | |
| BME: GRF Grifols, S.A. | Reiterated: Buy | €10.60 | €11.65 | -9.01% | 1 | Nov 25, 2025 | |
| GSK GSK plc | Reiterated: Sell | $48 → $23 | $50.45 | n/a | 4 | Oct 29, 2025 | |
| NVO Novo Nordisk | Reiterated: Hold | $135 → $56 | $41.63 | n/a | 37 | Oct 9, 2025 | |
| SWX: ROP Roche Holding AG | Upgraded: Buy | CHF 275.00 → CHF 340.00 | CHF 404.70 | n/a | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €110.00 → €205.00 | €149.60 | n/a | 3 | Jun 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $48 → $49 | $51.37 | n/a | 4 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $24 | $17.43 | n/a | 1 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $195 | $223.37 | n/a | 1 | Jan 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $60 | $28.89 | n/a | 1 | Nov 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $250.49 | n/a | 1 | May 2, 2016 |
AstraZeneca PLC
Oct 30, 2026
Reiterated: Buy
Price Target: n/a
Current: $13,982.00
Upside: -
GSK plc
Oct 28, 2026
Reiterated: Hold
Price Target: 2,350p
Current: 1,912p
Upside: +22.94%
Novartis AG
Oct 27, 2026
Reiterated: Buy
Price Target: CHF 150.00
Current: CHF 134.06
Upside: +11.89%
Novartis AG
Oct 27, 2026
Reiterated: Buy
Price Target: n/a
Current: $160.50
Upside: -
Sanofi
Oct 8, 2026
Reiterated: Hold
Price Target: €92.00
Current: €87.60
Upside: +5.02%
Bayer Aktiengesellschaft
Dec 2, 2025
Reiterated: Buy
Price Target: €30.00 → €35.00
Current: €56.52
Upside: -38.08%
Grifols, S.A.
Nov 25, 2025
Reiterated: Buy
Price Target: €10.60
Current: €11.65
Upside: -9.01%
GSK plc
Oct 29, 2025
Reiterated: Sell
Price Target: $48 → $23
Current: $50.45
Upside: n/a
Novo Nordisk
Oct 9, 2025
Reiterated: Hold
Price Target: $135 → $56
Current: $41.63
Upside: n/a
Roche Holding AG
Sep 13, 2024
Upgraded: Buy
Price Target: CHF 275.00 → CHF 340.00
Current: CHF 404.70
Upside: n/a
Jun 12, 2023
Reiterated: Buy
Price Target: €110.00 → €205.00
Current: €149.60
Upside: n/a
May 11, 2023
Reiterated: Buy
Price Target: $48 → $49
Current: $51.37
Upside: n/a
Feb 2, 2023
Reiterated: Hold
Price Target: $24
Current: $17.43
Upside: n/a
Jan 17, 2023
Reiterated: Hold
Price Target: $195
Current: $223.37
Upside: n/a
Nov 1, 2022
Reiterated: Buy
Price Target: $60
Current: $28.89
Upside: n/a
May 2, 2016
Reiterated: Buy
Price Target: n/a
Current: $250.49
Upside: n/a